← Back to Search

Saliva and NP paired specimen collection for Coronavirus

N/A
Waitlist Available
Led By Wenli Zhou, PhD
Research Sponsored by Paradigm Laboratories LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Persons referred for COVID-19 testing including those with COVID-19 symptoms and/or a suspected SARS-COV-2 infection or undergoing surveillance testing
Is able to give informed consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 hour
Awards & highlights

Study Summary

Upper respiratory swabs, such as the nasopharyngeal (NP) swab, have so far been major specimen sources used for the SARS-COV-2 molecular test. However, due to the discomfort and invasiveness of NP collection, and the expense of personal protective equipment, alternative sampling sources such as saliva are desired. The purpose of this proposed study is: 1) to examine whether saliva can be used as an specimen for the SARS-COV-2 molecular test; 2) to test if gingival crevicular fluids is a reliable specimen for the SARS-COV-2 antibodies.

Eligible Conditions
  • Coronavirus

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 hour
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 hour for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The clinical evaluation of saliva as specimen for COVID-19 molecular test

Trial Design

1Treatment groups
Experimental Treatment
Group I: Saliva and NP paired specimen collectionExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Paradigm Laboratories LLCLead Sponsor
Wenli Zhou, PhDPrincipal InvestigatorParadigm Laboratories

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~429 spots leftby Mar 2025